Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA

During a five-year trial of canakinumab, patients with systemic juvenile idiopathic arthritis taking canakinumab showed progress toward clinical remission and glucocorticoid tapering...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions canakinumab juvenile idiopathic arthritis (JIA) Pediatric sJIA Source Type: research